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Ovarian cancer is a deadly disease for which there is no eﬀective means of early detection. Ovarian carcinomas comprise a diverse
group of neoplasms, exhibiting a wide range of morphological characteristics, clinical manifestations, genetic alterations, and
tumor behaviors. This high degree of heterogeneity presents a major clinical challenge in both diagnosing and treating ovarian
cancer. Furthermore, the early events leading to ovarian carcinoma development are poorly understood, thus complicating eﬀorts
todevelopscreeningmodalitiesforthisdisease.Here,weprovideanoverviewofthecurrentmodelsofovariancancerpathogenesis,
highlighting recent ﬁndings implicating the fallopian tube ﬁmbria as a possible site of origin of ovarian carcinomas. The ovarian
cancer model will continue to evolve as we learn more about the genetics and etiology of this disease.
1.Introduction
Ovarian cancer aﬄicts ∼204000 women worldwide each
year, including ∼21650 Americans [1, 2]. Despite its rela-
tivelylowincidencerate,ovariancancerisanextremelylethal
disease. Globally, it claims 125000 lives per year, making it
the seventh leading cause of cancer-related deaths among
women [2]. In the United States, ovarian cancer mortality
is even higher; it ranks as the ﬁfth deadliest malignancy
among women, with an estimated 15520 deaths per year
[1]. In fact, of the top ten cancer types aﬄicting American
women in 2008, ovarian cancer had the highest death-to-
incidence ratio, exceeding even that of lung cancer [1]. Its
high mortality is primarily due to diﬃculties in diagnosing
earlystagedisease.Althoughthe5yearssurvivalrateforstage
I ovarian cancer is >90%, stage I diagnoses are more often
the exception than the rule. Most patients (∼75%) present
with advanced stage (III/IV) tumors, for which the 5years
survival rate is a dismal 30% [1]. This is not surprising when
one considers the anatomical problem—the ovaries are a
pair of tiny organs, only ∼2–4cm in diameter, suspended on
either side of the uterus and not readily accessible by pelvic
examination unless signiﬁcantly enlarged. By deﬁnition, a
stage I tumor is conﬁned to the ovary [3] and is therefore
unlikely to be noticed without the aid of a sensitive screening
test. Unfortunately, there are currently no eﬀective screening
modalities for detecting ovarian cancer in asymptomatic
individuals. Furthermore, there are no tell-tale physical signs
of the disease. Typical symptoms—which include abdominal
discomfort, bloating, gas, nausea, and urinary urgency—are
vague and often mistaken for gastrointestinal problems [4,
5]. In many cases, symptoms may not even present until the
tumor has reached an advanced stage. Consequently, ovarian
cancer is frequently nicknamed the “silent killer” [5–7].
2.EarlyDetection
The best tools currently available for detecting early-stage
ovarian cancer are transvaginal sonography (TVS) and
serum biomarker testing. TVS is a noninvasive technique
that provides detailed images of ovary size and shape,
facilitating the detection of ovarian masses. Large-scale
studies evaluating its ability to identify early-stage tumors
have reported mixed results [8–13]. Overall, TVS has not
demonstrated adequate sensitivity to warrant its use in
screening general populations. Furthermore, even in the
most optimistic reports, it is clear that TVS can only
detect tumors that cause a signiﬁcant increase in ovarian2 Journal of Oncology
volume [13]. This is especially worrisome in the case of
serous-type tumors which may spread rapidly from the
ovary to other pelvic sites prior to ovarian enlargement.
For instance, in a large study by van Nagell et al., four
women were diagnosed with late-stage ovarian cancer within
12months of a negative TVS scan [9]. In addition, there
is debate as to whether all ovarian tumors actually arise
from the ovary and not from adjacent pelvic sites such
as the fallopian tube or peritoneum [14]. Serous tumors
involving the ovary but originating from extraovarian sites
can never be classiﬁed as “stage I” according to current
staging systems, since they are never conﬁned to the ovary.
It has therefore been proposed that the deﬁnition of “early
stage”ovariancarcinomashouldbebasedonminimaltumor
volume rather than anatomical location [14]. TVS screening
may also be prone to false-positive results because it cannot
always distinguish malignant ovarian tumors from benign
adnexal masses, such as cysts and ﬁbromas, which are highly
prevalent among postmenopausal women [15, 16]. While
TVS alone is not a suitable front-line screening modality, it
can serve as a useful secondary screening tool after serum
biomarker testing [17, 18].
Serum biomarker testing is an ideal form of cancer
detection because it is minimally invasive, cost eﬀective,
easily administered, nonsubjective, and is not contingent
upon primary ovarian involvement. The most well-studied
ovariancancerbiomarkerisCA-125,ahighmolecularweight
transmembrane glycoprotein expressed by coelomic- and
M¨ ullerian-derived epithelia, including that of the fallopian
tube, endometrium, and endocervix [19]. It is not expressed
by normal ovarian epithelium [20]. CA-125 is detected at
low levels (<35 U/mL) in the serum of healthy individuals
but is elevated in ∼50% of stage I ovarian cancer patients
and ∼90% of advanced-stage patients [21–24]. CA-125
elevation is predominantly associated with serous tumors,
the most common and most lethal subtype of ovarian
carcinoma [25]. Serum levels directly correlate with the level
of CA-125 protein production in tumor cells and appear to
reﬂect a state of active tumor growth [25–27]. Following
its discovery in 1981 [28], CA-125 was intensely studied
to evaluate its potential for detecting early-stage ovarian
cancer, and many encouraging results were reported. For
example, a study of prediagnostic serum samples found
that CA-125 was elevated in 25% of ovarian cancer patients
5years prior to their diagnoses [29]. However, it was later
discovered that serum CA-125 levels can be increased by
a range of benign conditions (such as pelvic inﬂammatory
disease, endometriosis, uterine ﬁbroids, and ovarian cysts)
making false positivity a problem [30]. So far, CA-125 has
not demonstrated adequate sensitivity to support its use
in screening asymptomatic women for early-stage ovarian
cancer[31],butlonger-termstudiesarestillunderway.Inthe
meantime, CA-125 remains a valuable tool for monitoring
response to chemotherapy and for detecting disease relapse
following treatment [32, 33].
In an attempt to improve sensitivity for early disease
detection, two approaches have been taken. (1) Obtaining
longitudinal measurements of CA-125, and (2) using mul-
tiple tumor markers. The former approach assumes that CA-
125 levels are likely to remain stable in patients with benign
conditions but will increase over time if an ovarian cancer is
in progress. Thus, by plotting serial CA-125 measurements
over a period of years, one can calculate the “probability of
ovarian cancer” for an individual patient using a Bayesian
algorithm [34–36].
The latter approach aims to combine CA-125 with one
or more additional tumor markers, most notably human
epididymis protein 4 (HE4). HE4 is a glycoprotein secreted
byM¨ ullerianepitheliaofthefemalereproductivetractaswell
as male epididymis [37]. Like CA-125, it is not expressed by
normal ovarian epithelium but appears in some premalig-
nant ovarian cysts (cortical inclusion cysts) and is strongly
expressed by the most common ovarian tumor subtypes
(serous and endometrioid) [37]. HE4 is both more sensitive
and speciﬁc than CA-125 in detecting early-stage ovarian
cancer and is not associated with benign conditions to the
same degree, enabling HE4 to distinguish malignant ovarian
tumors from benign cystic lesions [38–40]. When used in
combination to detect early-stage disease, CA-125 and HE4
perform better than either marker alone and can be used
to stratify patients into high- and low-risk groups [40, 41].
Although HE4 was recently approved by the US Food and
Drug Administration for use in monitoring ovarian cancer
patientsfollowingtreatment,larger-scalestudiesarerequired
to determine whether a dual CA-125/HE4 biomarker test is
suitable for screening asymptomatic women in the general
population.
In addition, some groups have assembled panels of
biomarkers to create a so-called “composite marker.” For
example, Zhang et al. measured the serum levels of four
tumor markers (CA-125II, CA72-4, CA15-3, and M-CSF)
in sets of healthy women, women with benign ovarian
conditions, and women with ovarian cancer [42]. From
theirmeasurements,theyderivedanartiﬁcialneuralnetwork
(ANN) model that could distinguish healthy women from
those with early-stage ovarian cancer. The sensitivity of their
ANN-derived composite index was 25–28% higher than that
of CA-125 alone. Similar reports of increased sensitivity
upon employment of multiple tumor markers have been
reported by other groups [43, 44]. However, serum tests for
multiple biomarkers are not yet widely available.
3.OvarianCancer IsaHeterogeneous Disease
Some of the greatest challenges in detecting and treating
ovariancancerstemfromitsheterogeneousnature.Theterm
“ovarian cancer” refers not to a single disease, but to a
diverse group of malignancies aﬀecting the ovary. In general,
ovarian tumors may develop from one of three cell types:
epithelial cells, sex cord-stromal cells (including granulosa,
theca, and hilus cells), or germ cells (oocytes). Although
∼40% of all ovarian tumors are nonepithelial in origin, such
lesions rarely progress to a malignant state and account for
only 10% of ovarian cancers [45]. This paper will therefore
focusexclusivelyonepithelial-derivedovariantumors,which
constitute the predominant and most lethal forms of the
disease. Epithelial ovarian carcinomas are themselves a het-
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Figure 1: The major histologic subtypes of ovarian carcinoma. Serous carcinomas resemble fallopian tube epithelium, endometrioid
carcinomas resemble endometrial glands, and mucinous carcinomas resemble endocervical epithelium. Photographs show representative
tumor sections stained with hematoxylin and eosin. The shaded circle represents the general anatomical location from which ovarian
carcinomas are thought to arise. The pink and blue entities within the cross-sected ovary represent maturing ovarian follicles.
tumormorphologies,clinicalmanifestations,andunderlying
genetic alterations. Upon diagnosis of malignancy, ovarian
tumors are surgically staged to determine how far they have
extendedbeyondtheovary[3].StageIindicatesconﬁnement
to the ovary. Stage II tumors extend beyond the ovary to
adjacentpelvicstructuressuchasthefallopiantubeoruterus.
Stage III indicates metastasis to the peritoneum and/or
regional lymph nodes. Stage IV tumors have metastasized
beyond the peritoneum to distant sites. Additionally, tumors
are classiﬁed by subtype. Current clinical guidelines set forth
by the World Health Organization (WHO) recognize eight
histologic tumor subtypes: serous, endometrioid, mucinous,
clear cell, transitional cell, squamous cell, mixed epithelial,
and undiﬀerentiated [46].The three most common—serous,
endometrioid, and mucinous—are characterized by their
morphological resemblance to various mucosal tissues of
the female reproductive tract, all of which exhibit M¨ ullerian
diﬀerentiation (Figure 1). More speciﬁcally, serous tumors
resemble fallopian tube epithelium, endometrioid tumors
resemble endometrial glands, and mucinous tumors resem-
ble endocervical epithelium (though clinically, distinguish-
ing mucinous ovarian tumors from those of the gastroin-
testinal tract is more relevant) [47]. This phenomenon is
quite remarkable when one considers that all ovarian tumor
subtypesareconventionallythoughttodevelopfromovarian
surface epithelium, a monolayer of nondescript, poorly
diﬀerentiated mesothelial cells [48]. Within each subtype,
tumors are further described as either benign, malignant, or
borderline and, depending upon tumor subtype, classiﬁed as
low-orhigh-grade.Borderlinetumorsareconsideredtohave
low malignant potential and/or indolent behavior.
There are major diﬀerences in incidence, tumor behavior
(low versus high malignant potential), and clinical outcome
between each histologic subtype. For example, it has been
estimatedthat ∼50%ofmalignantovariantumorsareserous
carcinomas, while ∼25% are endometrioid carcinomas,
∼10% are mucinous carcinomas, and only ∼5% are clear
cell carcinomas [45] .H o w e v e r ,as t u d yb yS e i d m a ne t
al. reported incidences of 70%, 7%, 10%, and <3% for
serous, endometrioid, clear cell, and mucinous carcinomas,
respectively, in a series of 220 consecutive cases of invasive
ovarian cancer, suggesting that traditional distribution ﬁg-
u r e sm a yv a ryc o n s i d e ra b l y[ 49]. In terms of behavior, serous
carcinomas tend to be aggressive, high-grade neoplasms that
spread rapidly throughout the pelvis, while endometrioid
and mucinous carcinomas are typically low-grade lesions,
conﬁned to the ovary [50, 51]. Clear cell and endometri-
oid carcinomas, unlike other subtypes, are strongly linked
to endometriosis [52–56], leading some to believe that
endometriosis may be a precursor to these lesions [57, 58].
Tumor histology can also strongly impact clinical response.
Forinstance,late-stageserousandclearcellcarcinomas,both
of which have similar 5years survival rates (20–30%), diﬀer
markedly in their response to chemotherapy; serous tumors
are (initially) highly responsive, while clear cell tumors are
notoriously resistant [59, 60].4 Journal of Oncology
Genetic and biomarker proﬁling studies of ovarian
cancer have revealed that each tumor subtype is associated
with a unique “molecular signature.” For example, gene
expression proﬁling can readily distinguish mucinous and
clear cell ovarian tumors from other subtypes, regardless
of tumor stage or grade [61, 62]. Similarly, microRNA
(miRNA) proﬁling of ovarian carcinomas has identiﬁed
certain miRNAs that exhibit histotype speciﬁcity [63]. Gene
expression proﬁling has also demonstrated that ovarian clear
cell tumors are distinctly diﬀerent from other forms of ovar-
ian cancer and have more in common with clear cell tumors
ofotherorgans,suchasrenalclearcellcarcinomas[64].Even
within one histotype, diﬀerences in tumor behavior may
be underscored by distinct expression proﬁles. For example,
Bonome et al. found that serous borderline tumors (SBTs),
which account for 10–15% of serous ovarian neoplasms
and are associated with vastly improved survival, cluster
separatelyfromhigh-gradeserouscarcinomasinhierarchical
clustering analyses [65]. Moreover, SBTs are genetically
more similar to normal ovarian surface epithelium than
to advanced serous tumors. A recent immunohistochemical
biomarker study of 500 ovarian carcinomas found that 20
of 21 candidate tumor biomarkers had signiﬁcantly diﬀerent
expression patterns in each tumor subtype and that two
thirds of the biomarkers lost their prognostic value when
survival analyses were made subtype speciﬁc [66]. These
results clearly indicate that each ovarian tumor subtype
constitutes a distinct disease and should be treated as
such in the contexts of detection, treatment, and progno-
sis.
Perhaps the most important characteristic of any tumor
is the combination of genetic alterations that underlie
its development and drive its progression. In this arena,
ovarian tumors again exhibit heterogeneity. Mucinous,
endometrioid,andlow-gradeseroustumorstypicallyacquire
mutations in a variety of genes such as KRAS, BRAF,
PTEN, β-catenin,a n dTFG-βRII [51], all of which belong
to signaling pathways controlling cell growth and pro-
liferation, among other processes. Conversely, high-grade
serous tumors appear to arise following a mutation in TP53
[67] or, in the case of familial ovarian carcinoma, BRCA1,
BRCA2, MLH1,o rMSH2 [68, 69]. All ﬁve genes are tumor
suppressors that function in DNA damage signaling and
repair [69, 70], suggesting that DNA damage is an especially
importantfactorintheetiologyofserousovariancarcinoma.
Mutations in TP53 c a ne v e np r o m p ta ni m m u n o l o g i c a l
response, leading to p53 autoantibody production in some
patients with high-grade ovarian carcinomas [71].
Despite the high degree of phenotypic and genotypic
variability that exists between diﬀerent forms of ovarian
carcinoma, virtually all patients are treated identically upon
diagnosis:cytoreductivesurgery,followedbyplatinum-based
chemotherapy. Although many tumors are initially respon-
sive to this treatment, most develop platinum resistance
and ∼70% recur at some point [72]. Ultimately, only 30%
of advanced-stage patients survive ﬁve years beyond their
diagnoses [1]. Over the past several decades, great advances
havebeenmadeinthesurgicaltechniquesandchemotherapy
regimens used to treat ovarian cancer. Yet, despite the best
eﬀorts of surgeons, oncologists, and researchers, the 5years
survival rate has improved by only 8% since 1975 [1]. It has
thus become apparent that a “blanket approach” to ovarian
cancer treatment does not suﬃce. We must now shift our
focus towards the development of targeted therapies capable
of exploiting the molecular and genetic characteristics of
individual tumor subtypes. This task is made diﬃcult by
the fact that we are still very much in the dark when
it comes to understanding ovarian cancer etiology. Unlike
other malignancies such as cervical or colon cancer, whose
pathogeneses are well characterized, the sequence of events
leading to ovarian carcinoma development remains a subject
of ongoing debate.
4. Evolutionof the OvarianCancer Model
4.1. Ovarian Surface Epithelium and Cortical Inclusion Cysts.
The traditional view of ovarian cancer asserts that all tumor
subtypes share a common origin in ovarian surface epithe-
lium (OSE). OSE is a ﬂat-to-cuboidal layer of uncommitted
mesothelial cells covering the exterior surface of the ovary.
Duringovulation,follicularruptureandoocytereleaseinﬂict
physical trauma upon the ovarian surface, creating a breach
in the OSE that must be repaired. Over the course of a
woman’s reproductive life, this process of damage and repair
is repeated multiple times. Accordingly, OSE cells exhibit a
high degree of plasticity that facilitates tissue remodeling;
they express both epithelial and mesenchymal markers and
can transition from an epithelial to mesenchymal phenotype
[73–76]. In addition to physical trauma, OSE cells are
subjected to ovulation-associated inﬂammatory cytokines
and reactive oxygen species that are capable of damaging
DNA [77]. Accrual of DNA damage by OSE cells may
increase their susceptibility to transformation. Furthermore,
as women age, the ovarian surface develops numerous
invaginations into the cortical stroma. These invaginations
frequently pinch oﬀ and become entrapped within the
stroma, forming circular OSE-lined structures termed “cor-
tical inclusion cysts” (CICs) [78]. Once inside the ovary, the
epithelial cells lining CICs are exposed to a new hormone-
rich milieu that is thought to induce a diﬀerentiation or
“metaplasia” into more complex epithelium resembling that
of M¨ ullerian-derived organs [78, 79]. Alternatively, it is
postulated that in women experiencing endometriosis or
endosalpingiosis (i.e., abnormal shedding of endometrial
or tubal mucosa, respectively, into the pelvis), remnants
of M¨ ullerian-derived epithelia may adhere to the ovarian
surfaceandbecomeincorporatedintoaCIC[78,80].Several
hormones acting upon the ovary (e.g., gonadotropins, estro-
gens, and androgens) have growth-promoting properties
that may induce proliferation of epithelial cells within
CICs [81]. If the epithelial cells also happen to harbor
unresolved DNA damage, they may be prime targets for
neoplastic transformation, eventually giving rise to ovarian
carcinomas. The OSE-CIC model can account for several
important features of ovarian tumorigenesis, including (1)
acquisition of M¨ ullerian characteristics by OSE-derived
tumors, (2) the cystic nature of benign ovarian tumors
and the retention of cystic features by their malignantJournal of Oncology 5
counterparts, and (3) the presence of low-grade and bor-
derline tumors within the cortical stroma of the ovary. This
model is also consistent with well-established epidemiologic
data indicating that a decrease in ovulatory cycles (most
commonly due to parity or oral contraceptive use) is the
greatest risk-reducing factor for ovarian cancer in female
populations [82]. However, this model has its limitations.
For example, it does not explain why invasive endometrioid
and mucinous carcinomas are frequently associated with
borderline tumors in the ovary, whereas invasive serous
carcinomas are not. Nor does this model address the clear
diﬀerences in genetic alterations that exist between tumor
subtypes. If all ovarian tumors develop from CICs within
the ovary, then why do they have such diﬀerent outcomes
and such divergent genotypes? Perhaps the most curious
phenomenon, not accounted for by this model, is the exis-
tenceofextraovarianperitonealcarcinomas.Suchtumorsare
histologically identical to serous ovarian carcinomas but do
not involve the ovary and thus, are considered to arise de
novo in the peritoneum.
4.2. Two-Pathway Model. The two-pathway model was
proposed by Shih and Kurman in 2004 in an attempt
to integrate most of the clinical, histopathological, and
molecular genetic ﬁndings concerning ovarian cancer. In
particular, they sought to account for the diﬀerences in TP53
and KRAS mutational frequencies observed between serous
borderline tumors (SBTs) and serous carcinomas [83–85].
SBTs comprise a subset of serous ovarian tumors (including
those referred to as atypical proliferative serous tumors
and micropapillary serous carcinomas) that are noninvasive,
appear to develop from benign serous cystadenomas, and
progress very slowly towards low-grade serous carcinoma
[86, 87]. The indolent behavior of SBTs contrasts sharply
with that of conventional high-grade serous tumors, which
spread rapidly and metastasize early in their course. Fur-
thermore, SBTs do not harbor the TP53 mutations that
are characteristic of high-grade serous carcinomas. These
observations prompted the formulation of a new model that
c l a s s i ﬁ e sa l lo v a r i a nt u m o r sa se i t h e rT y p eIo rT y p eI I[ 51].
Type I tumors include all major histotypes (serous,
endometrioid, mucinous, clear cell, and transitional) but
exhibit low-grade nuclear and architectural features, slow
growth, and can be linked to well-deﬁned benign ovarian
precursorlesions.Themostcommongeneticalterationsseen
among Type I tumors are KRAS and BRAF mutations, both
of which activate the oncogenic MAPK signaling pathway
[88]. Mutually exclusive KRAS and BRAF mutations are
observed in ∼65% of SBTs but are rarely seen in high-
g r a d es e r o u sc a r c i n o m a s[ 58, 89]. KRAS mutations also
occur in ∼60% of mucinous, 5–16% of clear cell, and 4-5%
of endometrioid Type I carcinomas [51]. PTEN mutations,
which typically result in constitutive PI3K signaling, occur
in ∼20% of Type I endometrioid neoplasms [90]. The
MAPK and PI3K pathways are related; they eventually
converge upon a common downstream translation factor,
eIF4B [91], which may represent an important signaling
axis in Type I tumor development. WNT and TGF-β
signaling pathways are also of potential importance for Type
I tumor pathogenesis, based on the presence of β-catenin
mutations in 16–54% of endometrioid tumors and TGF-
β RII mutations in 66% of Type I clear cell tumors [51].
Interestingly,allofthegenesalteredinTypeIovariantumors
are components of pathways that become intimately related
during the process of epithelial-to-mesenchymal transition
[92, 93].
Type II ovarian tumors, on the other hand, are infre-
quently associated with benign or borderline ovarian precur-
sor lesions. They are comprised almost exclusively of high-
grade serous carcinomas but also include two less common
subtypes—mixed epithelial and undiﬀerentiated carcino-
mas. Type II ovarian tumors are overwhelmingly TP53
mutated (50–80%) and may also exhibit gene ampliﬁcation
and overexpression of HER2/neu (10–20%) and AKT2 (12–
18%) oncogenes [94–99]. Shih and Kurman’s two-pathway
hypothesis reconciles most of the phenotypic and genotypic
observations pertaining to ovarian tumors and it certainly
improves upon the conventional OSE-CIC model. However,
their model leaves one critical question unanswered—how
do Type II tumors arise and does their pathogenesis include
a well-deﬁned precursor lesion?
4.3. Fallopian Tube as a Site of Origin. This question may
have been answered by a series of studies investigating
the prevalence of occult fallopian tube cancer in women
with germline BRCA gene mutations. Inherited mutations
in BRCA1o rBRCA2 are associated with familial ovarian
and breast cancer syndromes and account for ∼11–15% of
ovarian carcinomas [100]. Mutations in either gene confer
a 15–40% lifetime risk of developing ovarian cancer [101].
ManywomenwithgermlineBRCAmutations(BRCA+)elect
to undergo risk-reducing bilateral salpingo-oophorectomy
(ovary and fallopian tube removal), after which their ovaries
are thoroughly examined for evidence of occult cancer.
Until recently, the fallopian tubes were not closely examined
following such surgeries, and thus, early-stage tubal cancers
were rarely detected and severely under reported in BRCA+
patients.
In 2001, Piek et al. drew attention to this issue when they
reported that sectioning and examination of fallopian tubes
from 12 BRCA+ patients revealed a high incidence (50%)
of epithelial dysplasia [102]. The fallopian tube epithelium
(FTE) is a columnar cell layer composed of two specialized
cell types—secretory and ciliated cells. In their study, Piek
et al. noticed that dysplastic regions of FTE exhibited a
shift towards the secretory phenotype, with complete loss
of ciliated cells and the acquisition of proliferative capacity
(indicated by Ki67 immunoreactivity). Shortly thereafter,
several other groups reported ﬁnding occult tubal cancers in
the fallopian tubes of BRCA+ women, with incidence rates
ranging from 0.9–17% [103–105].
However, not until a few years later did it become
apparent that the distal end of the fallopian tube, the
“ﬁmbria”, rather than the proximal region of the tube, was
the most crucial site to look for early serous tumors. In
2006, Medeiros et al. conducted a study similar to that of
Piek et al., examining the fallopian tubes of 13 BRCA+
women undergoing bilateral salpingo-oophorectomy [106].6 Journal of Oncology
Medeiros et al. employed a speciﬁc protocol for Sectioning
and Extensively Examining the FIMbria (SEE-FIM). Their
examination uncovered a high incidence (38%) of serous
tubal intraepithelial carcinomas in the fallopian tube, but
none in the ovaries. Furthermore, 80% of these carcinomas
appeared exclusively in the ﬁmbriated end of the fallopian
tube, indicating that the ﬁmbria is the preferred site of
serous carcinogenesis in BRCA+ women. Similarly, Callahan
et al. reported on a cohort of 122 BRCA+w o m e ni n
which 7 early carcinomas were found, all originating in the
ﬁmbrial/ampullary region. A third study by Kindelberger et
al. documented the occurrence of tubal intraepithelial carci-
nomas (TICs) in 55 consecutive cases of pelvic (i.e., ovarian,
tubal, and peritoneal) serous cancer, not selected for BRCA
status [107]. Of 42 cases designated “serous ovarian carci-
noma,” 71% involved the fallopian tube, and 48% of these
contained a TIC. Again, TICs were located predominantly
(93%) in the ﬁmbrial region. These results suggest that many
high-grade serous “ovarian” tumors may actually be of tubal
origin, arising from the distal region of the fallopian tube,
but then quickly spreading to the nearby ovary.
This concept, while at ﬁrst provocative, is quite plausible
uponconsideration.Theﬁmbrialiesinextremelycloseprox-
imity to ovarian surface epithelium and is therefore exposed
to the same inﬂammatory (and potentially carcinogenic)
microenvironment. At the ﬁmbriated end of the tube the
internal tubal mucosa (endosalpinx) meets the outer tubal
serosa which, in turn, is continuous and indistinguishable
from the peritoneum. It is therefore easy to imagine that
transformed FTE cells, early in their progression, may
slough oﬀ and migrate to the ovarian surface or directly
to the peritoneum, with minimal ovarian involvement. This
could explain the existence of some extraovarian peritoneal
carcinomas.
During their initial study of tubal mucosa [106],
Medeirosetal.notedstretchesofsecretory-typecellsexhibit-
ing strong p53 immunoreactivity but appearing nonpro-
liferative and histologically benign. The observed loss of
ciliated cells was reminiscent of dysplastic lesions earlier
described by Piek et al. [102]. They termed these regions of
strong p53 immunoreactivity “p53 signatures” (Figure 2). In
an attempt to further characterize these entities, Lee et al.
examined the occurrence of p53 signatures in the ﬁmbria of
bothBRCA+womenandwomenundergoinghysterectomies
for benign indications (such as ﬁbroids, endometriosis, or
prolapse) [108]. They found that p53 signatures were equally
common in the nonneoplastic ﬁmbria of both BRCA+
and control subjects, suggesting that they are a “normal”
phenomenon. They also discovered that p53 signatures stain
strongly for the DNA damage marker γ-H2AX (Figure 2).
Gamma-H2AX is a phosphorylated form of the histone
protein H2AX. Phosphorylation of H2AX by DNA damage-
sensing kinases ATM and ATR occurs rapidly at sites of DNA
double strand breakage [109]. The presence of so-called “p53
signatures” in the ﬁmbriae of normal women provides the
ﬁrst evidence that, under normal physiologic conditions,
ﬁmbrial epithelial cells experience genotoxic damage and
trigger a DNA damage response. Lee et al.’s study also made
several key observations about the relationship between p53
signatures and TICs: 1 p53 signatures occur more frequently
in ﬁmbriae where TICs are also present, 2 p53 signatures
are composed exclusively of secretory cells which, like TICs,
exhibit a serous phenotype, 3 p53 signatures and TICs, when
concurrent, share evidence of DNA damage and exhibit
identical TP53 mutations, indicating a common origin, and
4 TICs can be distinguished from p53 signatures by their
increased proliferative capacity (i.e., MIB1 positivity and
increased Cyclin E expression). Based on their observations,
Lee et al. hypothesized that p53 signatures could represent
theelusiveovarianserouscarcinomaprecursor.Todetermine
whether p53 signatures also occur in ovarian epithelium,
Folkins et al. examined the ovaries and fallopian tubes of
75 BRCA+ women. They detected a total of 29 signatures
in tubal mucosa but only 1 in OSE and 0 in CICs [110],
conﬁrming that p53 signatures preferentially arise in FTE
rather than OSE.
In light of these developments, Lee et al. formulated
a model of ovarian cancer which incorporates the ﬁmbria
as a major site of origin for serous carcinomas. Their
model asserts that there are two distinct pathways leading
to ovarian tumorigenesis. The ﬁrst route is the traditional
OSE-CIC pathway, in which OSE (or in some cases FTE,
endometrium, or peritoneum) is entrapped within CICs and
induced to undergo M¨ ullerian metaplasia within the ovarian
stroma, giving rise to mostly endometrioid, mucinous, and
serous borderline tumors via a series of step-wise mutations
(reviewed in [111]). This pathway leads to the formation of
Shih and Kurman’s “Type I” tumors. The second pathway
involves the fallopian tube ﬁmbria, where a combination
of TP53 mutation and genotoxic stress leads to the clonal
expansion of secretory epithelial cells, forming a pre-
neoplastic precursor lesion or “p53 signature.” Additional
genetic “hits” in the absence of functional TP53 enable
these cells to acquire a proliferative capacity, facilitating
progression to TIC (Figure 3). Identifying the genetic targets
of such “hits” is currently a subject of intense research.
Serous TICs have the ability to spread rapidly, moving
from the ﬁmbria to adjacent pelvic structures (e.g., the
ovarian surface, uterine serosa, or peritoneal membranes) or
exfoliating into the peritoneal cavity. This second pathway
leads to the formation of Shih and Kurman’s “Type II”
tumors and, importantly, deﬁnes a precursor lesion for
these tumors. The origin of genotoxic stress in the ﬁmbrial
microenvironment remains speculative at this point but is
thought to include inﬂammatory cytokines and reactive oxy-
gen species associated with ovulation. Accordingly, a recent
paper has reported that p53 signatures are associated with
lower parity in BRCA+ women, suggesting that ovulation
is indeed a risk factor for p53 signature development in the
ﬁmbria [112].
This new model of ovarian cancer accounts for nearly all
aspects of the disease and, for the ﬁrst time, describes a step-
by-step pathogenesis model for the deadliest and most enig-
matic of all ovarian tumors—serous carcinoma. The clinical
implications of this model were recently reviewed [111, 113]
and suggest that a thorough examination of the fallopian
tube ﬁmbria should be conducted during routine patho-













Figure 2: Pathologic features of the morphological continuum from normal fallopian tube epithelium to invasive serous carcinoma. Normal
fallopian tube epithelium (FTE),containing both secretory (thick arrow) and ciliated (thin arrow) cells, is typically immunonegative for p53,
γ-H2AX (a marker of DNA damage), and MIB1 (antibody against Ki67; a proliferation marker). The benign “p53 signature” is composed of
a stretch of secretory cells exhibiting strong p53 expression and evidence of DNA damage (i.e., nuclear γ-H2AX foci), but showing no signs
of proliferation. Upon progression to TIC, there is an acquisition of proliferative capacity, as evidenced by gain of MIB1 immunoreactivity.
High levels of p53, γ-H2AX, and MIB1 typically persist after a TIC develops into invasive serous carcinoma.
important to note, however, that this new model is based
largely upon descriptive pathological evidence and has not
been experimentally validated.
5. ExperimentalModels of OvarianCancer
In order to elucidate the molecular mechanisms driving
ovarian carcinoma development, we must ﬁrst be able to
model the disease using suitable in vitro and in vivo systems.
Several sophisticated mouse models of ovarian carcinoma
currently exist. Most are based on the traditional OSE-
CIC model of ovarian tumorigenesis and therefore seek to
transform murine ovarian surface epithelium (MOSE) in
vivo. For example, Connolly et al. induced MOSE transfor-
mation in vivo by introducing SV40 T-Ag (large and small)
into these cells under the control of a M¨ ullerian inhibitory
substance II receptor (MISIIR) promoter element [114].
Other groups have used the Cre-Lox system to conditionally
knockout tumor suppressor genes TP53 and Rb in murine
ovaries [115]. Orsulic et al. developed a unique model in
which a series of oncogenes was introduced directly into the
MOSE cells of an adult mouse [116]. Their system employed
an avian retroviral vector that requires retroviral receptor












of peritoneum or ovary
Figure 3:Diagramofaﬁmbrialplica,illustratingthestepwiseprogressionofnormalfallopiantubeepitheliumtoinvasiveserouscarcinoma.
The fallopian tube epithelium (FTE) is composed of a single layer of ciliated and secretory cells that are exposed to ovulation-associated
inﬂammatory cytokines and reactive oxygen species (ROS). Repetitive genotoxic stress causes DNA damage and induces p53 mutation, lead-
ing to the clonal expansion of normal looking FTE cells of secretory phenotype. This stretch of damaged cells—termed a “p53 signature”—
stains strongly for p53 and γ-H2AX. Further genetic “hits” enable cells to acquire a proliferative capacity, giving rise to tubal intraepithelial
carcinoma (TIC). As a TIC progresses to invasive serous carcinoma, malignant cells are exfoliated from the ﬁmbria, whereupon they may
spread rapidly to the surface of the peritoneum and/or ovary. Exfoliation may also occur from TICs prior to ﬁmbrial invasion.
by breeding transgenic animals that express TVA under the
control of a tissue-speciﬁc gene promoter. However, since
no MOSE-speciﬁc promoters exist, they removed the ovaries
from a TVA expressing mouse, infected them in vitro, then
implanted them orthotopically into a recipient mouse. Using
this method, they were able to demonstrate the importance
of TP53 in suppressing ovarian tumorigenesis. Speciﬁcally,
they showed that introduction of a trio of oncogenes (c-
MYC, KRAS,a n dAKT) into p53+/+ MOSE could not induce
tumor formation, while introducing any two of the same
oncogenes induced rapid tumor formation in p53
−/− mice.
All three of these models gave rise to poorly diﬀerentiated
tumors resembling serous ovarian carcinomas and exhibited
intraperitoneal dissemination.
There have also been attempts to create subtype-
speciﬁc mouse models. Dinulescu et al. successfully gener-
ated tumors with endometrioid histology by using the Cre-
Lox system to conditionally activate oncogenic KRAS and
inactivatePTEN [117].Usingthissystem,theydemonstrated
that expression of activated KRAS or deletion of PTEN in
MOSE led to an endometriosis-like condition, characterized
by the presence of benign glandular lesions in the ovary.
In contrast, the combination of both genetic mutations
induced formation of invasive and metastatic adenocarci-
nomas resembling human ovarian endometrioid tumors.
Their model nicely recapitulates the stepwise progression of
T y p eIo v a r i a nt u m o r s .H o w e v e r ,KRAS mutations are not
commonly found in the endometrioid subtype. A second
endometrioid tumor model developed by Wu et al. used the
Cre-Lox system to delete PTEN and APC tumor suppressor
genes,againgivingrisetotumorswithendometrioidhistolo-
gies [118]. Although APC mutations are not characteristic of
endometrioid ovarian carcinomas, they serve to deregulate
the same pathway as β-catenin mutations—speciﬁcally, the
WNT signaling pathway.
Mouse models that can faithfully reproduce both the
genotypic and phenotypic characteristics of ovarian tumors
arecrucialforthedevelopmentoftargetedtherapies.Current
ovarian carcinoma models indicate that there are two
divergent pathways to ovarian tumorigenesis, each giving
rise to tumors with very diﬀerent characteristics (Types I
and II). In attempting to model these tumor types, it is
important to consider that many Type II tumors may arise
from extraovarian sites—most notably, the fallopian tube
epithelium. This is of critical importance, for example, in the
context of orthotopic tumor cell implantation.
Recent revelations regarding the tubal origin of high-
gradeserousovariancarcinomaspresentachallengebecause,
while human OSE cells have been routinely cultured for
many years, FTE cells are a relatively scare commodity. There
are no readily available human FTE cell lines and primary
human FTE can be diﬃcult to obtain. Nevertheless, modelsJournal of Oncology 9
of FTE must be created in order to study the mechanisms of
tubal/ovarian serous carcinoma development. Only a hand-
ful of labs thus far have attempted to culture or propagate
FTE cells in vitro, the majority of them working within
the ﬁeld of reproductive biology [119–124]. As mentioned
earlier, the FTE is a complex columnar epithelium composed
of both secretory and ciliated cell types. However, ciliated
FTE cells tend to either die or rapidly dediﬀerentiate when
grown in vitro, resulting in a complete loss of the ciliated
cell phenotype from FTE cocultures. Serous tubal/ovarian
carcinomas are exclusively secretory in nature, suggesting
that ciliated cells must be either less susceptible to malignant
transformationormoreapttoundergocelldeathinresponse
to genotoxic stressors in their microenvironment. To address
such issues, a model system is required in which both ciliated
and secretory cells remain viable, so that the behaviors of
each cell type may be readily compared and contrasted.
To preserve the phenotypic integrity of FTE cocultures,
they may be grown on collagen-coated porous ﬁlters, as
described by Rajagopal et al. for the culture of monkey
oviductal cells [125]. Similar techniques have been used to
construct polarized cultures of respiratory epithelial cells
[126]. Our lab has recently established an analogous “ex
vivo” model of human FTE (unpublished data). Using this
F T Ec o c u l t u r es y s t e mw ea i mt oa n s w e rs e v e r a li m p o r t a n t
questions, including the following: What are the molecular
mechanisms driving FTE malignant transformation? Can
transformedFTEcellsprogresstoseroustubalintraepithelial
carcinoma? Which molecules may be targeted in a therapeu-
tic context to halt serous carcinoma progression? Are there
FTE-speciﬁc genes that can be exploited for the development
of a tubal serous carcinoma mouse model? Can we identify
novel biomarkers relevant to serous tumor progression? Our
studies must ultimately also consider the role of the tumor
microenvironment, since it is apparent that multicellular
interactions contribute to serous tumor metastasis and
are important factors in a therapeutic context [127, 128].
Overall, these research eﬀorts will oﬀer new insights into
the nature of the FTE and its propensity for malignant
transformation, and thus, advance our understanding of
ovarian cancer pathogenesis.
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